|
1
|
Tuder RM, Abman SH, Braun T, et al:
Development and pathology of pulmonary hypertension. J Am Coll
Cardiol. 54:S3–S9. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McLaughlin VV, Davis M and Cornwell W:
Pulmonary arterial hypertension. Curr Probl Cardiol. 36:461–517.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Voelkel NF, Gomez-Arroyo J, Abbate A,
Bogaard HJ and Nicolls MR: Pathobiology of pulmonary arterial
hypertension and right ventricular failure. Eur Respir J.
40:1555–1565. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tuder RM, Marecki JC, Richter A,
Fijalkowska I and Flores S: Pathology of pulmonary hypertension.
Clin Chest Med. 28:23–42. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rabinovitch M: Molecular pathogenesis of
pulmonary arterial hypertension. J Clin Invest. 118:2372–2379.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xu W and Erzurum SC: Endothelial cell
energy metabolism, proliferation, and apoptosis in pulmonary
hypertension. Compr Physiol. 1:357–372. 2011.PubMed/NCBI
|
|
7
|
Guignabert C, Raffestin B, Benferhat R, et
al: Serotonin transporter inhibition prevents and reverses
monocrotaline-induced pulmonary hypertension in rats. Circulation.
111:2812–2819. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Masri FA, Xu W, Comhair SA, et al:
Hyperproliferative apoptosis-resistant endothelial cells in
idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell
Mol Physiol. 293:L548–L554. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Choi AM, Ryter SW and Levine B: Autophagy
in human health and disease. N Engl J Med. 368:651–662. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Slomovitz BM and Coleman RL: The
PI3K/AKT/mTOR pathway as a therapeutic target in endometrial
cancer. Clin Cancer Res. 18:5856–5864. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang X, Li L, Niu X, et al: mTOR enhances
foam cell formation by suppressing the autophagy pathway. DNA Cell
Biol. 33:198–204. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ryter SW, Nakahira K, Haspel JA and Choi
AM: Autophagy in pulmonary diseases. Annu Rev Physiol. 74:377–401.
2012. View Article : Google Scholar
|
|
13
|
Zhang H, Gong Y, Wang Z, et al: Apelin
inhibits the proliferation and migration of rat PASMCs via the
activation of PI3K/Akt/mTOR signal and the inhibition of autophagy
under hypoxia. J Cell Mol Med. 18:542–553. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mizumura K, Cloonan SM, Haspel JA and Choi
AM: The emerging importance of autophagy in pulmonary diseases.
Chest. 142:1289–1299. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nyfeler B, Bergman P, Wilson CJ and Murphy
LO: Quantitative visualization of autophagy induction by mTOR
inhibitors. Methods Mol Biol. 821:239–250. 2012. View Article : Google Scholar
|
|
16
|
Jung CH, Ro SH, Cao J, Otto NM and Kim DH:
mTOR regulation of autophagy. FEBS Lett. 584:1287–1295. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang X, Li W, Hou Y, Niu Z, Zhong Y,
Zhang Y and Yang S: Comparative membrane proteomic analysis between
lung adenocarcinoma and normal tissue by iTRAQ labeling mass
spectrometry. Am J Transl Res. 6:267–280. 2014.PubMed/NCBI
|
|
18
|
Veyssier-Belot C and Cacoub P: Role of
endothelial and smooth muscle cells in the physiopathology and
treatment management of pulmonary hypertension. Cardiovasc Res.
44:274–282. 1999. View Article : Google Scholar
|
|
19
|
Perros F, Dorfmüller P, Souza R, et al:
Fractalkine-induced smooth muscle cell proliferation in pulmonary
hypertension. Eur Respir J. 29:937–943. 2007. View Article : Google Scholar
|
|
20
|
Laplante M and Sabatini DM: mTOR signaling
in growth control and disease. Cell. 149:274–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang X, Li L, Li M, et al: Knockdown of
mTOR by lentivirus-mediated RNA interference suppresses
atherosclerosis and stabilizes plaques via a decrease of
macrophages by autophagy in apolipoprotein E-deficient mice. Int J
Mol Med. 32:1215–1221. 2013.PubMed/NCBI
|
|
22
|
Zoncu R, Efeyan A and Sabatini DM: mTOR:
from growth signal integration to cancer, diabetes and ageing. Nat
Rev Mol Cell Biol. 12:21–35. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Stenmark KR, Fagan KA and Frid MG:
Hypoxia-induced pulmonary vascular remodeling cellular and
molecular mechanisms. Circ Res. 99:675–691. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Orr R, Smith LJ and Cuttica MJ: Pulmonary
hypertension in advanced chronic obstructive pulmonary disease.
Curr Opin Pulm Med. 18:138–143. 2012. View Article : Google Scholar
|
|
25
|
Hoshikawa Y, Ono S, Suzuki S, et al:
Generation of oxidative stress contributes to the development of
pulmonary hypertension induced by hypoxia. J Appl Physiol.
90:1299–1306. 2001.PubMed/NCBI
|
|
26
|
Mizushima N: Autophagy: process and
function. Genes Dev. 21:2861–2873. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kuma A, Matsui M and Mizushima N: LC3, an
autophagosome marker, can be incorporated into protein aggregates
independent of autophagy. Autophagy. 3:323–328. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gomez-Arroyo JG, Farkas L, Alhussaini AA,
et al: The monocrotaline model of pulmonary hypertension in
perspective. Am J Physiol Lung Cell Mol Physiol. 302:L363–L369.
2012. View Article : Google Scholar
|
|
29
|
Long L, Yang X, Southwood M, et al:
Chloroquine prevents progression of experimental pulmonary
hypertension via inhibition of autophagy and lysosomal bone
morphogenetic protein type II receptor degradation. Circ Res.
112:1159–1170. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ravikumar B, Vacher C, Berger Z, et al:
Inhibition of mTOR induces autophagy and reduces toxicity of
polyglutamine expansions in fly and mouse models of Huntington
disease. Nat Genet. 36:585–595. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schaefer CA, Kuhlmann CRW, Weiterer S, et
al: Statins inhibit hypoxia-induced endothelial proliferation by
preventing calcium-induced ROS formation. Atherosclerosis.
185:290–296. 2006. View Article : Google Scholar
|
|
32
|
Tuder RM, Groves B, Badesch DB and Voelkel
NF: Exuberant endothelial cell growth and elements of inflammation
are present in plexiform lesions of pulmonary hypertension. Am J
Pathol. 144:275–285. 1994.PubMed/NCBI
|
|
33
|
Yu L and Hales CA: Hypoxia does neither
stimulate pulmonary artery endothelial cell proliferation in mice
and rats with pulmonary hypertension and vascular remodeling nor in
human pulmonary artery endothelial cells. J Vasc Res. 48:465–475.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Porter KM, Kang BY, Adesina SE, Murphy TC,
Hart CM and Sutliff RL: Chronic hypoxia promotes pulmonary artery
endothelial cell proliferation through
H2O2-induced 5-lipoxygenase. PloS One.
9:e985322014. View Article : Google Scholar
|
|
35
|
Kang BY, Kleinhenz JM, Murphy TC and Hart
CM: The PPARγ ligand rosiglitazone attenuates hypoxia-induced
endothelin signaling in vitro and in vivo. Am J Physiol Lung Cell
Mol Physiol. 301:L881–L891. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Poon A, Eidelman D, Laprise C and Hamid Q:
ATG5, autophagy and lung function in asthma. Autophagy. 8:694–695.
2012. View Article : Google Scholar : PubMed/NCBI
|
